WHO Prequalification Programme issues new EOI

On May 30, the WHO issued its third invitation to manufacturers of reproductive health (RH) products to submit an Expression of Interest (EOI) for product evaluation to the WHO Prequalification Programme. Three new RH products are now invited for Prequalification:

• Injectable hormonal contraceptives: medroxyprogesterone acetate  + estradiol cypronate,  injection 25 mg + 5 mg
• Implantable contraceptives: two-rod levonorgestrel-releasing implant,  each rod containing 75 mg of levonorgestrel (150 mg in total)
• Oxytocics: mifepristone + misoprostol,  co-packaged mifepristone 200 mg tablet and 4 tablets of misoprostol 200 micrograms

For further information, consult the invitation announcement on http://healthtech.who.int/pq/info_applicants/eoi/EOI_ReproductiveHealth-V3.pdf, the WHO web site at http://www.who.int/prequal, or contact Angela Lopes of the Prequalification Programme.

Categories: Collaboration, Featured, Market Development Approaches Working Group, Systems Strengthening Working Group